Piper Jaffray PJC
-
Anthera Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
… President Analysts Marko K. Kozul - Leerink Swann LLC, Research Division Christopher Mortko Edward A. Tenthoff - Piper Jaffray Companies , Research Division Heather Behanna - JMP Securities LLC, Research Division Presentation Operator Good day …
-
XenoPort's CEO Presents at Special Conference (Transcript)
… Financial Officer Vincent J. Angotti – Executive Vice President and Chief Operating Officer Analysts Rebecca M. Forest – Piper Jaffray , Inc. Brian C. Abrahams – Wells Fargo Securities LLC Marko Kozul – Leerink Swann LLC Presentation Operator Good …
-
Derma Sciences' CEO Discusses Q1 2013 Results - Earnings Call Transcript
… Finance Barry Wolfenson - Group President of Advanced Wound Care and Pharmaceutical Development Analysts David Amsellem - Piper Jaffray Scott Henry - ROTH Capital William Plovanic - Canaccord Genuity Presentation Operator Welcome to the Derma Sciences …
-
Athersys Management Discusses Q1 2013 Results - Earnings Call Transcript
… Executive Officer Analysts Stephen G. Brozak - WBB Securities, LLC, Research Division Edward A. Tenthoff - Piper Jaffray Companies , Research Division Jason Kolbert - Maxim Group LLC, Research Division Greg Chodaczek - First Analysis Securities …
-
Alexza Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
… King - Chief Executive Officer, President, Director and Chairman of Finance Committee Analysts Roy Buchanan - Piper Jaffray Companies , Research Division Patricia L. Bank - DISCERN Investment Analytics, Inc Scott R. Henry - Roth Capital Partners …
-
Theravance's CEO discusses 1 Billion Dollar Royalty Participation Agreement with Elan (Transcript)
… Mike Aguiar – SVP and CFO Rick Winningham – Chairman and CEO Analysts Howard Liang – Leerink Swann Ian Somaiya – Piper Jaffray Ronny Gal – Sanford C. Bernstein & Company Alexander Robinson – Tenor Capital Management Company Stephen Willey …
-
New Morningstar Analyst Report for Piper Jaffray Companies
… could have lasted an indeterminate amount of time. Piper Jaffray materially increased its relatively stable and high ..... slightly decreasing our fair value estimate for Piper Jaffray Companies to $36 per share from $38 per share. The decrease …
-
We Are Reducing Our Uncertainty Rating for Piper Jaffray Companies
We are reducing our uncertainty rating for Piper Jaffray Companies PJC to high from very high. The reduction is primarily a result of increased clarity regarding the company’s earnings after it restructured …
-
Horizon Pharma CEO Discuses Q1 2013 Results - Earnings Call Transcript
… President and CEO Todd Smith - EVP and CCO Analyst Annabel Samimy - Stifel Heather Biana - JMP Securities Charles Duncan - Piper Jaffray Presentation Operator Good morning, ladies and gentlemen. And welcome to Horizon Pharma Inc. First Quarter 2013 Earnings …
-
Sequenom's CEO Discusses Q1 2013 Results - Earnings Call Transcript
… Dirk van den Boom - EVP, Research and Development and CTO Marcy Graham - Senior Director, IR Analysts Dave Clair - Piper Jaffray Zarak Khurshid - Wedbush Securities Matthew O'Brien - William Blair & Co. Eric Chang - Oppenheimer & Co. Bryan …